STING1 and neoplasm: Since STING agonists are being activelyexplored as cancer immunotherapeutics and diABZI-based agonists (e.g.,GSK3745417) have entered clinical trials (NCT03843359), we next soughtto validate the antitumor activity of diABZI-PEG and diABZI-DMA constructsin mouse tumor models.